JCAR014
Drug
Celgene Corporation
Total Payments
$289,624
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $289,624 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $289,624 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma4 (2639) | Celgene Corporation | $289,624 | 0 |
Top Doctors Receiving Payments for JCAR014
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $289,624 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $289,624
Product Information
- Type Drug
- Total Payments $289,624
- Total Doctors 0
- Transactions 1
About JCAR014
JCAR014 is a drug associated with $289,624 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2019 to 2019. In 2019, $289,624 was paid across 1 transactions to 0 doctors.
The most common payment nature for JCAR014 is "Unspecified" ($289,624, 100.0% of total).
JCAR014 is associated with 1 research study, including "Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma4 (2639)" ($289,624).